Hirokazu Tanaka

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
No aliases are listed.
Publication record
125 papers · 2,679 citations · H-index 28

PAPERS

Prospective observational study to assess the prognosis of patients with myeloproliferative neoplasms in Japan (MPN-15): results of baseline analysis.
20260 citationsauthor #22
Insights into very elderly multiple myeloma treatment from Kansai Myeloma Forum
20250 citationsauthor #8
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study
20241 citationsauthor #12
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients
20242 citationsauthor #19
Depletion of Ppp6c in hematopoietic and vascular endothelial cells causes embryonic lethality and decreased hematopoietic potential.
20240 citationsauthor #2
The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients
20240 citationsauthor #10
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin
20235 citationsauthor #10
Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum
20231 citationsauthor #25
Long-term effectiveness and safety of high dose chemotherapy followed by autologous stem cell transplantation in daily practice in patients with diffuse large B-cell lymphoma
20238 citationsauthor #17
Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma Forum
20232 citationsauthor #9
H2S産生酵素cystathionine-β-synthaseを阻害するカルビドパとベンセラジドはボルテゾミブ感受性および抵抗性多発性骨髄腫細胞の生存を抑制する
20230 citationsauthor #9
Inhibition of endogenous H2S production suppresses the viability of multiple myeloma cells: application of carbidopa and benserazide capable of inhibiting cystathionine-β-synthase to treatment of bortezomib-resistant multiple myeloma
20220 citationsauthor #9
Monocyte or white blood cell counts and β2 microglobulin predict the durable efficacy of daratumumab with lenalidomide
20224 citationsauthor #14
Novel prognostic predictor of haemoglobin–platelet index in diffuse large B‐cell lymphoma, not otherwise specified: Anaemia and thrombocytopenia are associated with IL‐6 production in lymphoma cells
20224 citationsauthor #3
CD34+ myeloma cells with self-renewal activities are therapy-resistant and persist as MRD in cell cycle quiescence
20224 citationsauthor #2
Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells.
20229 citationsauthor #11
C-type lectin-like receptor 2 specifies a functionally distinct subpopulation within phenotypically defined hematopoietic stem cell population that contribute to emergent megakaryopoiesis
20222 citationsauthor #2
Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis
20229 citationsauthor #9
Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis
202112 citationsauthor #14
Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial
20214 citationsauthor #13
MO23-2 Significance of maintenance therapies in symptomatic multiple myeloma patients with HDT/ASCT
20210 citationsauthor #5
Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma
20211 citationsauthor #13
Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum
20210 citationsauthor #6
Potent efficacy of chlorpromazine in acute myeloid leukemia harboring KIT-D816V mutation
20212 citationsauthor #2
Decreased expression of T‐cell‐associated immune markers predicts poor prognosis in patients with follicular lymphoma
202117 citationsauthor #15
Decreased Expression of T-Cell-Associated Immune Markers Predicts Poor Prognosis in Patients with Advanced Follicular Lymphoma Received Rituximab Plus Bendamustine
20210 citationsauthor #15
Tumour‐immune microenvironment in duodenal‐type follicular lymphoma
202010 citationsauthor #3
Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum registry
202010 citationsauthor #13
The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia
20206 citationsauthor #13
[Pathology and treatment of multiple myeloma understood from the tumor cell-of-origin perspective].
20200 citationsauthor #1
Epstein–Barr Virus-Induced Post-Transplant Lymphoproliferative Disorder of the Central Nervous System Successfully Treated with Chemo-Immunotherapy
20204 citationsauthor #3
A Phase 1 Study Evaluating Safety and Tolerability of Navitoclax Monotherapy in Japanese Patients with Myeloproliferative Neoplasms
20200 citationsauthor #2
Introduction by the Guest Editor: Recent advances in biology and treatment of multiple myeloma
20202 citationsauthor #1
Targeted therapy for medullary and extramedullary relapse of FLT3-ITD acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation
202012 citationsauthor #3
Retrospective analysis of plasmacytoma in Kansai Myeloma Forum Registry
20203 citationsauthor #2
Inhibitors of H2S-generating enzymes reduce the survival of human multiple myeloma-derived KMS-11 cells with resistance to bortezomib, a proteasome inhibitor
20200 citationsauthor #4
Chlorpromazine eliminates acute myeloid leukemia cells by perturbing subcellular localization of FLT3-ITD and KIT-D816V
202025 citationsauthor #2
Severe Eosinophilia in Myelodysplastic Syndrome With a Defined and Rare Cytogenetic Abnormality
20196 citationsauthor #4
Excessive Reactive Iron Impairs Hematopoiesis by Affecting Both Immature Hematopoietic Cells and Stromal Cells
201931 citationsauthor #1
Multiple cytokine-producing B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classic Hodgkin lymphoma with autoimmune hemolytic anemia
20190 citationsauthor #8
Multiple cytokine-producing aggressive EBV-positive diffuse large B cell lymphoma, not otherwise specified with hemophagocytic syndrome
20191 citationsauthor #8
Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab
20181 citationsauthor #2
Gastric microbiota: An emerging player in Helicobacter pylori-induced gastric malignancies.
201893 citationsauthor #3
Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum
201817 citationsauthor #18
Retrospective analysis of primary plasma cell leukemia in Kansai Myeloma Forum registry
20186 citationsauthor #22
Immunemodulatory Effects of 5-Azacitidin Through Expansion of Functional Regulatory T Cells on Paraneoplastic Inflammation Associated With Myelodysplastic Syndromes: A Case Report
20185 citationsauthor #2
Interleukin‐17‐producing angioimmunoblastic T‐cell lymphoma with Evans syndrome
20181 citationsauthor #3
Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B Cell Lymphoma and Acute Myeloid Leukemia
20186 citationsauthor #6
Azacitidine therapy for low-risk myelodysplastic syndrome developing after solid organ transplantation.
20170 citationsauthor #7
Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms
201722 citationsauthor #2
[Successful treatment of secondary graft failure with donor lymphocyte infusion in a post-allogeneic stem cell transplant acute myeloid leukemia patient].
20170 citationsauthor #6
ESAM is a novel human hematopoietic stem cell marker associated with a subset of human leukemias.
201627 citationsauthor #3
Second primary malignancies among patients with myeloma-related-diseases in the KMF database.
20161 citationsauthor #8
ESAM Is a Novel Human Hematopoietic Stem Cell Marker Associated with a Subset of Human Leukemias
20151 citationsauthor #3
HIV-negative Primary Bone Marrow Hodgkin Lymphoma Manifesting with a High Fever Associated with Hemophagocytosis as the Initial Symptom: A Case Report and Review of the Previous Literature.
20157 citationsauthor #9
[Molecular mechanisms in the resistance of CML stem cells to tyrosine kinase inhibitors and novel targets for achieving a cure].
20153 citationsauthor #1
Mice doubly‐deficient in the Arf GAPs SMAP1 and SMAP2 exhibit embryonic lethality
20155 citationsauthor #14
Targeting intracellular trafficking of FLT3-ITD and KIT D816V by chlorpromazine shows promising preclinical activity against acute myeloid leukemia cells
20150 citationsauthor #2
CALM plays a critical role for oncogenic activity of RTK mutants and would be a promising therapeutic target
20150 citationsauthor #1
Deficiency of CALM accompanies with reduced melanin production in mouse melanoma B16C2M cells.
20150 citationsauthor #8
P1-2-3Analysis of gemcitabine therapy for relapsed or refractory malignant lymphoma in one institute
20150 citationsauthor #6
Aleukemic solitary cutaneous myeloid sarcoma
20152 citationsauthor #3
Endothelial cell-selective adhesion molecule is a novel human hematopoietic stem cell marker associated with a subset of human leukemias
20150 citationsauthor #3
Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma
201410 citationsauthor #7
Chlorpromazine, an Inhibitor of Intracellular Trafficking of FLT3-ITD and KIT D816V, Shows Prominent Anti-Leukemic Activities Against AML Cells and AML Stem Cells in Vitro and in Vivo.
20142 citationsauthor #2
〈Originals〉Trib1 and Trib2 inhibit granulocytic differentiation by suppressing Akt pathway
20140 citationsauthor #8
Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents
201416 citationsauthor #4
The anti-apoptotic gene Anamorsin is essential for both autonomous and extrinsic regulation of murine fetal liver hematopoiesis.
20145 citationsauthor #9
O2-4-2CLINICAL COURSES OF 133 MGUS AND 73 SMOLDERING MULTIPLE MYELOMA REGISTERED IN KANSAI MYELOMA FORUM
20140 citationsauthor #5
Tribl and Trib2 inhibit granulocytic differentiation by suppressing Akt pathway
20140 citationsauthor #9
Clathrin Assembly Protein CALM Plays a Critical Role in KIT Signaling by Regulating Its Cellular Transport from Early to Late Endosomes in Hematopoietic Cells
201428 citationsauthor #2
Successful anticoagulant therapy for two pregnant PNH patients, and prospects for the eculizumab era
201311 citationsauthor #4
Successful allogeneic hematopoietic stem cell transplantation in a young patient with Richter syndrome presenting with chronic lymphocytic leukemia and diffuse large B-cell lymphoma with different cell origins.
20131 citationsauthor #7
The Satb1 protein directs hematopoietic stem cell differentiation toward lymphoid lineages.
2013111 citationsauthor #13
Sub-acute demyelinating polyradiculoneuropathy as an initial symptom of peripheral T cell lymphoma, not otherwise specified (PTCL-NOS).
20127 citationsauthor #5
[Molecular target therapy for myelodysplastic syndrome].
20120 citationsauthor #2
Quiescence and Self-Renewal Hematopoietic Stem Cell Status between The Endothelial Antigen ESAM Monitors
20120 citationsauthor #10
C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells
201241 citationsauthor #3
IS5. hematological malignancies
20120 citationsauthor #1
The Endothelial Antigen ESAM Monitors Hematopoietic Stem Cell Status between Quiescence and Self-Renewal
201231 citationsauthor #10
The Clathrin Assembly Protein PICALM Is Required for Erythroid Maturation and Transferrin Internalization in Mice
201254 citationsauthor #2
PICOT is a molecule which binds to anamorsin.
201132 citationsauthor #3
A cell-death-defying factor, anamorsin mediates cell growth through inactivation of PKC and p38MAPK.
201114 citationsauthor #3
An Anti-Apoptotic Molecule, Anamorsin, Functions in Both Iron-Sulfur Protein Assembly and Cellular Iron Homeostasis
20112 citationsauthor #3
Myeloid neoplasm-related gene abnormalities differentially affect dendritic cell differentiation from murine hematopoietic stem/progenitor cells.
20116 citationsauthor #5
Satb1 Determines Hematopoietic Stem Cell Differentiation Toward the Lymphoid Lineages
20110 citationsauthor #10
A Cell-Death-Defying Factor, Anamorsin, Contributes Cell Growth through Binding with PICOT and Inactivation of PKCs and p38MAPK.
20100 citationsauthor #4
A Chromatin Modifier SATB1 Promotes Lymphocyte Production From Primitive Hematopoietic Stem/Progenitor Cells
20101 citationsauthor #3
BCR-ABL but Not JAK2 V617F Inhibits Erythropoiesis through the Ras Signal by Inducing p21CIP1/WAF1*
201017 citationsauthor #3
Myeloid Neoplasm-Related Gene Abnormalities Differentially Affect FLT3-Ligand Mediated Dendritic Cell Differentiation From Murine Hematopoietic Stem/Progenitor Cells
20100 citationsauthor #5
FIP1L1-PDGFRα Imposes Eosinophil Lineage Commitment on Hematopoietic Stem/Progenitor Cells*
200929 citationsauthor #8
C-Terminal Mutation of RUNX1 Deteriorates DNA Damage-Repair Response and Promotes the Development of Acute Myeloid Leukemia.
20091 citationsauthor #3
SIRT1 Deficiency Suppresses the Maintenance of Hematopoietic Stem Cell Pool.
20082 citationsauthor #3
Roles for the AML1/RUNX1 Point Mutation in the Pathogenesis of MDS/AML.
20080 citationsauthor #3
AML1/RUNX1 Works as a Negative Regulator of c-Mpl in Hematopoietic Stem Cells*
200847 citationsauthor #3
AML 1 / RUNX 1 Works as a Negative Regulator of c-Mpl in Hematopoietic Stem Cells *
20085 citationsauthor #3
Wnt/β-Catenin Pathway Affects the Cell-Fate Decisions of Hematopoietic Stem/Progenitor Cells Modulating the Epigenetic States of Various Essential Transcription Factors
20081 citationsauthor #1
FIP1L1/PDGFRα Imposes Commitment towards Eosinophil Lineage on Hematopoietic Stem/Progenitor Cells by Modifying the Expression and Function of Lineage Specific Transcription Factors.
20070 citationsauthor #7
HOX decoy peptide enhances the ex vivo expansion of human umbilical cord blood CD34+ hematopoietic stem cells/hematopoietic progenitor cells.
20068 citationsauthor #1
Canonical NF-κ B Pathway Is Required for Early Mesodermal Differentiation from the Murine Embryonic Stem Cells.
20061 citationsauthor #1

TIMELINE

1998 33 citations

1999 364 citations

2000 324 citations

2001 61 citations

2002 323 citations

2003 215 citations

2004 327 citations

2005 91 citations

2006 75 citations

2007 0 citations

2008 55 citations

2009 30 citations

2010 18 citations

2011 54 citations

2012 133 citations

2013 123 citations

2014 61 citations

2015 18 citations

2016 28 citations

2017 22 citations

2018 129 citations

2019 38 citations

2020 72 citations

2021 36 citations

2022 32 citations

2023 16 citations

2024 3 citations

2025 0 citations

2026 0 citations

Hirokazu Tanaka

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT